University of Leicester
Browse
Protocol and rationale for the first South Asian 5-year prospective longitudinal observational cohort study and biomarker evaluation investigating the clinical course and risk profile of IgA nephropathy: GRACE IgANI cohort.pdf (572.59 kB)

Protocol and rationale for the first South Asian 5-year prospective longitudinal observational cohort study and biomarker evaluation investigating the clinical course and risk profile of IgA nephropathy: GRACE IgANI cohort.

Download (572.59 kB)
journal contribution
posted on 2019-08-30, 15:17 authored by S Alexander, GT John, A Korula, TS Vijayakumar, VG David, A Mohapatra, AT Valson, S Jacob, PM Koshy, G Rajan, EE John, SM Matthai, L Jeyaseelan, B Ponnusamy, T Cook, C Pusey, MR Daha, J Feehally, J Barratt, S Varughese
Background: IgA nephropathy (IgAN) is the most common primary glomerulonephritis and an important cause of end-stage kidney disease. Unlike the slowly progressive course seen among Caucasian and East Asian subjects (actuarial survival 80-85% over 10 years), in India about 30-40% of patients have nephrotic syndrome and renal dysfunction at presentation and a 10-year renal survival of 35%, as reported from a retrospective registry. These observations cannot be entirely attributed to a lack of uniform screening protocols or late referral and attest to the probability that IgAN may not be the same disease in different parts of the world. Methods: We will prospectively recruit 200 patients with IgAN (the GRACE IgANI- Glomerular Research And Clinical Experiments- Ig A Nephropathy in Indians-cohort) and stratify them into low and high risk of progression based on published absolute renal risk scores. We will test the validity of this risk score in an unselected Indian IgAN population over a 5-year follow-up period. In parallel, we will undertake extensive exploratory serum, urine, renal and microbiome biomarker studies, firstly, to determine if the underlying pathogenic pathways are the same in Indian IgAN compared to those reported in Caucasian and East Asian IgAN. Secondly, we will systematically assess the value of measuring selected biomarkers and adding this data to traditional measures of risk in IgAN to predict kidney failure. We ultimately hope to generate a composite IgAN risk score specific for the Indian population. Ethics and data dissemination: Approval was obtained from the Institutional Review Board (Silver, Research and Ethics Committee) of the Christian Medical College, Vellore, India (Ref. No. IRB Min. No. 8962 [Other] dated 23.07.2014 and IRB Min. No. 9481 [Other] dated 24.06.2015). It is anticipated that results of this study will be presented at national and international meetings, with reports being published from late 2018.

Funding

This work is supported by the Wellcome Trust/DBT India Alliance Fellowship (grant number 501501). S.A. is a Wellcome Trust/DBT India Alliance Early Career Fellow (Clinical and Public Health). Initial small funding was by a major fluid research internal grant [8962 (Other) dated 23.07.2014] from Christian Medical College, Vellore-632004, India.

History

Citation

Wellcome Open Research 2018, 3:91

Author affiliation

/Organisation/COLLEGE OF LIFE SCIENCES/School of Medicine/Department of Infection, Immunity and Inflammation

Version

  • VoR (Version of Record)

Published in

Wellcome Open Research 2018

Publisher

F1000Research, Wellcome Trust

issn

2398-502X

eissn

2398-502X

Copyright date

2018

Available date

2019-08-30

Publisher version

https://wellcomeopenresearch.org/articles/3-91/v1

Notes

Supplementary File 1. Completed STROBE checklist for this study. https://wellcomeopenresearch.s3.amazonaws.com/supplementary/14644/b9e04f75-c3ed-4646-8d9e-6f84731bc840.docx

Language

en

Usage metrics

    University of Leicester Publications

    Categories

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC